nodes	percent_of_prediction	percent_of_DWPC	metapath
Loperamide—ABCB1—melanoma	0.253	1	CbGaD
Loperamide—CYP3A4—Temozolomide—melanoma	0.0634	0.284	CbGbCtD
Loperamide—CYP2D6—Vemurafenib—melanoma	0.0546	0.245	CbGbCtD
Loperamide—ABCB1—Dactinomycin—melanoma	0.0385	0.173	CbGbCtD
Loperamide—CYP3A4—Vemurafenib—melanoma	0.0347	0.156	CbGbCtD
Loperamide—ABCB1—Docetaxel—melanoma	0.0199	0.0892	CbGbCtD
Loperamide—POMC—skin epidermis—melanoma	0.0139	0.149	CbGeAlD
Loperamide—CYP3A4—Docetaxel—melanoma	0.0119	0.0534	CbGbCtD
Loperamide—POMC—blood vessel—melanoma	0.00928	0.0998	CbGeAlD
Loperamide—POMC—neck—melanoma	0.00664	0.0714	CbGeAlD
Loperamide—CALM2—ear—melanoma	0.00513	0.0551	CbGeAlD
Loperamide—CALM1—ear—melanoma	0.0051	0.0549	CbGeAlD
Loperamide—POMC—skin of body—melanoma	0.0043	0.0462	CbGeAlD
Loperamide—Altered state of consciousness—Temozolomide—melanoma	0.00313	0.0437	CcSEcCtD
Loperamide—POMC—head—melanoma	0.0028	0.0302	CbGeAlD
Loperamide—CALM2—endothelium—melanoma	0.00275	0.0296	CbGeAlD
Loperamide—CALM1—endothelium—melanoma	0.00274	0.0294	CbGeAlD
Loperamide—CALM2—hair follicle—melanoma	0.0027	0.0291	CbGeAlD
Loperamide—CACNA1A—head—melanoma	0.00268	0.0288	CbGeAlD
Loperamide—CALM2—blood vessel—melanoma	0.00254	0.0273	CbGeAlD
Loperamide—CALM1—blood vessel—melanoma	0.00252	0.0271	CbGeAlD
Loperamide—Bullous eruption—Docetaxel—melanoma	0.00243	0.034	CcSEcCtD
Loperamide—Toxic epidermal necrolysis—Vemurafenib—melanoma	0.00185	0.0258	CcSEcCtD
Loperamide—CALM2—neck—melanoma	0.00181	0.0195	CbGeAlD
Loperamide—CALM1—neck—melanoma	0.00181	0.0194	CbGeAlD
Loperamide—CALM3—eye—melanoma	0.00172	0.0185	CbGeAlD
Loperamide—CALM3—retina—melanoma	0.0017	0.0183	CbGeAlD
Loperamide—Stevens-Johnson syndrome—Vemurafenib—melanoma	0.00157	0.0219	CcSEcCtD
Loperamide—OPRD1—head—melanoma	0.00155	0.0166	CbGeAlD
Loperamide—OPRK1—head—melanoma	0.00148	0.016	CbGeAlD
Loperamide—Depressed level of consciousness—Carmustine—melanoma	0.00145	0.0202	CcSEcCtD
Loperamide—Depressed level of consciousness—Temozolomide—melanoma	0.0014	0.0195	CcSEcCtD
Loperamide—CALM3—mammalian vulva—melanoma	0.00136	0.0147	CbGeAlD
Loperamide—Ileus—Docetaxel—melanoma	0.00136	0.019	CcSEcCtD
Loperamide—CALM2—eye—melanoma	0.00135	0.0145	CbGeAlD
Loperamide—Erythema multiforme—Vemurafenib—melanoma	0.00134	0.0188	CcSEcCtD
Loperamide—CALM1—eye—melanoma	0.00134	0.0144	CbGeAlD
Loperamide—CALM2—retina—melanoma	0.00134	0.0144	CbGeAlD
Loperamide—CALM1—retina—melanoma	0.00133	0.0143	CbGeAlD
Loperamide—CALM2—skin of body—melanoma	0.00117	0.0126	CbGeAlD
Loperamide—CALM1—skin of body—melanoma	0.00117	0.0126	CbGeAlD
Loperamide—CALM2—mammalian vulva—melanoma	0.00107	0.0115	CbGeAlD
Loperamide—CALM1—mammalian vulva—melanoma	0.00107	0.0115	CbGeAlD
Loperamide—OPRM1—head—melanoma	0.00106	0.0113	CbGeAlD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.00105	0.0146	CcSEcCtD
Loperamide—Toxic epidermal necrolysis—Dactinomycin—melanoma	0.00105	0.0146	CcSEcCtD
Loperamide—Anaphylactic shock—Vemurafenib—melanoma	0.00101	0.0141	CcSEcCtD
Loperamide—ABCB1—blood vessel—melanoma	0.00101	0.0108	CbGeAlD
Loperamide—Nervous system disorder—Vemurafenib—melanoma	0.000991	0.0138	CcSEcCtD
Loperamide—Skin disorder—Vemurafenib—melanoma	0.000981	0.0137	CcSEcCtD
Loperamide—Toxic epidermal necrolysis—Temozolomide—melanoma	0.000946	0.0132	CcSEcCtD
Loperamide—Abdominal distension—Temozolomide—melanoma	0.000914	0.0128	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Dactinomycin—melanoma	0.000887	0.0124	CcSEcCtD
Loperamide—CYP2B6—skin of body—melanoma	0.000873	0.00938	CbGeAlD
Loperamide—Gastrointestinal disorder—Vemurafenib—melanoma	0.000872	0.0122	CcSEcCtD
Loperamide—Fatigue—Vemurafenib—melanoma	0.000871	0.0122	CcSEcCtD
Loperamide—Constipation—Vemurafenib—melanoma	0.000864	0.0121	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Temozolomide—melanoma	0.000803	0.0112	CcSEcCtD
Loperamide—Clotrimazole—CYP17A1—melanoma	0.000788	0.364	CrCbGaD
Loperamide—CALM2—head—melanoma	0.000766	0.00824	CbGeAlD
Loperamide—CALM1—head—melanoma	0.000762	0.0082	CbGeAlD
Loperamide—Erythema multiforme—Dactinomycin—melanoma	0.00076	0.0106	CcSEcCtD
Loperamide—Hypersensitivity—Vemurafenib—melanoma	0.000744	0.0104	CcSEcCtD
Loperamide—Dermatitis bullous—Docetaxel—melanoma	0.000731	0.0102	CcSEcCtD
Loperamide—Asthenia—Vemurafenib—melanoma	0.000725	0.0101	CcSEcCtD
Loperamide—Urinary tract disorder—Temozolomide—melanoma	0.000718	0.01	CcSEcCtD
Loperamide—Pruritus—Vemurafenib—melanoma	0.000715	0.00997	CcSEcCtD
Loperamide—Urethral disorder—Temozolomide—melanoma	0.000712	0.00994	CcSEcCtD
Loperamide—Diarrhoea—Vemurafenib—melanoma	0.000691	0.00965	CcSEcCtD
Loperamide—Erythema multiforme—Temozolomide—melanoma	0.000687	0.00959	CcSEcCtD
Loperamide—CALM3—lymph node—melanoma	0.000683	0.00734	CbGeAlD
Loperamide—Dizziness—Vemurafenib—melanoma	0.000668	0.00932	CcSEcCtD
Loperamide—Immune system disorder—Temozolomide—melanoma	0.000656	0.00916	CcSEcCtD
Loperamide—Vomiting—Vemurafenib—melanoma	0.000642	0.00896	CcSEcCtD
Loperamide—Abdominal pain upper—Docetaxel—melanoma	0.000638	0.0089	CcSEcCtD
Loperamide—Rash—Vemurafenib—melanoma	0.000637	0.00889	CcSEcCtD
Loperamide—Dermatitis—Vemurafenib—melanoma	0.000636	0.00888	CcSEcCtD
Loperamide—Headache—Vemurafenib—melanoma	0.000633	0.00883	CcSEcCtD
Loperamide—Discomfort—Bleomycin—melanoma	0.000631	0.0088	CcSEcCtD
Loperamide—Toxic epidermal necrolysis—Docetaxel—melanoma	0.000629	0.00878	CcSEcCtD
Loperamide—Anaphylactic shock—Bleomycin—melanoma	0.000612	0.00854	CcSEcCtD
Loperamide—Nausea—Vemurafenib—melanoma	0.0006	0.00837	CcSEcCtD
Loperamide—Discomfort—Dactinomycin—melanoma	0.000588	0.00821	CcSEcCtD
Loperamide—Angioedema—Temozolomide—melanoma	0.000578	0.00807	CcSEcCtD
Loperamide—CYP2B6—head—melanoma	0.000569	0.00612	CbGeAlD
Loperamide—CALM2—lymph node—melanoma	0.000536	0.00577	CbGeAlD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000535	0.00746	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Docetaxel—melanoma	0.000534	0.00745	CcSEcCtD
Loperamide—CALM1—lymph node—melanoma	0.000534	0.00574	CbGeAlD
Loperamide—Discomfort—Temozolomide—melanoma	0.000532	0.00743	CcSEcCtD
Loperamide—ABCB1—retina—melanoma	0.000531	0.00571	CbGeAlD
Loperamide—Dry mouth—Temozolomide—melanoma	0.000527	0.00735	CcSEcCtD
Loperamide—Anaphylactic shock—Temozolomide—melanoma	0.000516	0.00721	CcSEcCtD
Loperamide—Nervous system disorder—Temozolomide—melanoma	0.000506	0.00707	CcSEcCtD
Loperamide—Skin disorder—Temozolomide—melanoma	0.000502	0.007	CcSEcCtD
Loperamide—Fatigue—Dactinomycin—melanoma	0.000492	0.00687	CcSEcCtD
Loperamide—Urticaria—Bleomycin—melanoma	0.000486	0.00679	CcSEcCtD
Loperamide—Urinary tract disorder—Docetaxel—melanoma	0.000477	0.00666	CcSEcCtD
Loperamide—Somnolence—Carmustine—melanoma	0.000475	0.00663	CcSEcCtD
Loperamide—Urethral disorder—Docetaxel—melanoma	0.000474	0.00661	CcSEcCtD
Loperamide—Gastrointestinal pain—Dactinomycin—melanoma	0.000467	0.00651	CcSEcCtD
Loperamide—Gastrointestinal disorder—Carmustine—melanoma	0.000461	0.00644	CcSEcCtD
Loperamide—Somnolence—Temozolomide—melanoma	0.000459	0.00641	CcSEcCtD
Loperamide—Erythema multiforme—Docetaxel—melanoma	0.000457	0.00638	CcSEcCtD
Loperamide—Constipation—Carmustine—melanoma	0.000457	0.00638	CcSEcCtD
Loperamide—Dyspepsia—Temozolomide—melanoma	0.000455	0.00634	CcSEcCtD
Loperamide—Abdominal pain—Dactinomycin—melanoma	0.000451	0.0063	CcSEcCtD
Loperamide—Hypersensitivity—Bleomycin—melanoma	0.000451	0.00629	CcSEcCtD
Loperamide—Gastrointestinal disorder—Temozolomide—melanoma	0.000446	0.00622	CcSEcCtD
Loperamide—Fatigue—Temozolomide—melanoma	0.000445	0.00621	CcSEcCtD
Loperamide—Constipation—Temozolomide—melanoma	0.000442	0.00616	CcSEcCtD
Loperamide—Asthenia—Bleomycin—melanoma	0.000439	0.00613	CcSEcCtD
Loperamide—Gastrointestinal pain—Carmustine—melanoma	0.000437	0.0061	CcSEcCtD
Loperamide—Immune system disorder—Docetaxel—melanoma	0.000437	0.00609	CcSEcCtD
Loperamide—Pruritus—Bleomycin—melanoma	0.000433	0.00604	CcSEcCtD
Loperamide—ABCB1—mammalian vulva—melanoma	0.000425	0.00457	CbGeAlD
Loperamide—CYP2D6—head—melanoma	0.000423	0.00455	CbGeAlD
Loperamide—Abdominal pain—Carmustine—melanoma	0.000422	0.00589	CcSEcCtD
Loperamide—Gastrointestinal pain—Temozolomide—melanoma	0.000422	0.00589	CcSEcCtD
Loperamide—Hypersensitivity—Dactinomycin—melanoma	0.000421	0.00587	CcSEcCtD
Loperamide—Urticaria—Temozolomide—melanoma	0.00041	0.00572	CcSEcCtD
Loperamide—Asthenia—Dactinomycin—melanoma	0.00041	0.00572	CcSEcCtD
Loperamide—Abdominal pain—Temozolomide—melanoma	0.000408	0.0057	CcSEcCtD
Loperamide—Hypersensitivity—Carmustine—melanoma	0.000394	0.00549	CcSEcCtD
Loperamide—Diarrhoea—Dactinomycin—melanoma	0.000391	0.00545	CcSEcCtD
Loperamide—Vomiting—Bleomycin—melanoma	0.000389	0.00543	CcSEcCtD
Loperamide—Rash—Bleomycin—melanoma	0.000386	0.00539	CcSEcCtD
Loperamide—Dermatitis—Bleomycin—melanoma	0.000386	0.00538	CcSEcCtD
Loperamide—Asthenia—Carmustine—melanoma	0.000383	0.00535	CcSEcCtD
Loperamide—Hypersensitivity—Temozolomide—melanoma	0.00038	0.00531	CcSEcCtD
Loperamide—Asthenia—Temozolomide—melanoma	0.00037	0.00517	CcSEcCtD
Loperamide—Loss of consciousness—Docetaxel—melanoma	0.00037	0.00516	CcSEcCtD
Loperamide—Diarrhoea—Carmustine—melanoma	0.000366	0.0051	CcSEcCtD
Loperamide—Pruritus—Temozolomide—melanoma	0.000365	0.0051	CcSEcCtD
Loperamide—Nausea—Bleomycin—melanoma	0.000364	0.00507	CcSEcCtD
Loperamide—Vomiting—Dactinomycin—melanoma	0.000363	0.00507	CcSEcCtD
Loperamide—Rash—Dactinomycin—melanoma	0.00036	0.00502	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.000356	0.00496	CcSEcCtD
Loperamide—Dizziness—Carmustine—melanoma	0.000353	0.00493	CcSEcCtD
Loperamide—Diarrhoea—Temozolomide—melanoma	0.000353	0.00493	CcSEcCtD
Loperamide—Dry mouth—Docetaxel—melanoma	0.00035	0.00489	CcSEcCtD
Loperamide—Anaphylactic shock—Docetaxel—melanoma	0.000343	0.00479	CcSEcCtD
Loperamide—Dizziness—Temozolomide—melanoma	0.000341	0.00476	CcSEcCtD
Loperamide—Vomiting—Carmustine—melanoma	0.00034	0.00474	CcSEcCtD
Loperamide—Nausea—Dactinomycin—melanoma	0.000339	0.00473	CcSEcCtD
Loperamide—Rash—Carmustine—melanoma	0.000337	0.0047	CcSEcCtD
Loperamide—Nervous system disorder—Docetaxel—melanoma	0.000337	0.0047	CcSEcCtD
Loperamide—Dermatitis—Carmustine—melanoma	0.000337	0.0047	CcSEcCtD
Loperamide—Headache—Carmustine—melanoma	0.000335	0.00467	CcSEcCtD
Loperamide—Skin disorder—Docetaxel—melanoma	0.000334	0.00465	CcSEcCtD
Loperamide—Vomiting—Temozolomide—melanoma	0.000328	0.00458	CcSEcCtD
Loperamide—Rash—Temozolomide—melanoma	0.000326	0.00454	CcSEcCtD
Loperamide—Dermatitis—Temozolomide—melanoma	0.000325	0.00454	CcSEcCtD
Loperamide—Headache—Temozolomide—melanoma	0.000323	0.00451	CcSEcCtD
Loperamide—Tamoxifen—CYP1B1—melanoma	0.000323	0.149	CrCbGaD
Loperamide—Nausea—Carmustine—melanoma	0.000317	0.00443	CcSEcCtD
Loperamide—Nausea—Temozolomide—melanoma	0.000307	0.00428	CcSEcCtD
Loperamide—Somnolence—Docetaxel—melanoma	0.000305	0.00426	CcSEcCtD
Loperamide—ABCB1—head—melanoma	0.000304	0.00327	CbGeAlD
Loperamide—Dyspepsia—Docetaxel—melanoma	0.000302	0.00422	CcSEcCtD
Loperamide—Gastrointestinal disorder—Docetaxel—melanoma	0.000296	0.00414	CcSEcCtD
Loperamide—Fatigue—Docetaxel—melanoma	0.000296	0.00413	CcSEcCtD
Loperamide—Constipation—Docetaxel—melanoma	0.000294	0.0041	CcSEcCtD
Loperamide—Gastrointestinal pain—Docetaxel—melanoma	0.000281	0.00392	CcSEcCtD
Loperamide—Abdominal pain—Docetaxel—melanoma	0.000271	0.00379	CcSEcCtD
Loperamide—Hypersensitivity—Docetaxel—melanoma	0.000253	0.00353	CcSEcCtD
Loperamide—Asthenia—Docetaxel—melanoma	0.000246	0.00344	CcSEcCtD
Loperamide—Pruritus—Docetaxel—melanoma	0.000243	0.00339	CcSEcCtD
Loperamide—Diarrhoea—Docetaxel—melanoma	0.000235	0.00328	CcSEcCtD
Loperamide—Toremifene—ABCB1—melanoma	0.000232	0.107	CrCbGaD
Loperamide—Dizziness—Docetaxel—melanoma	0.000227	0.00317	CcSEcCtD
Loperamide—Vomiting—Docetaxel—melanoma	0.000218	0.00305	CcSEcCtD
Loperamide—Rash—Docetaxel—melanoma	0.000217	0.00302	CcSEcCtD
Loperamide—Dermatitis—Docetaxel—melanoma	0.000216	0.00302	CcSEcCtD
Loperamide—Headache—Docetaxel—melanoma	0.000215	0.003	CcSEcCtD
Loperamide—ABCB1—lymph node—melanoma	0.000213	0.00229	CbGeAlD
Loperamide—Nausea—Docetaxel—melanoma	0.000204	0.00285	CcSEcCtD
Loperamide—Fexofenadine—ABCB1—melanoma	0.000203	0.0938	CrCbGaD
Loperamide—Clotrimazole—ABCB1—melanoma	0.000157	0.0725	CrCbGaD
Loperamide—Haloperidol—ABCB1—melanoma	0.000141	0.0653	CrCbGaD
Loperamide—Fentanyl—ABCB1—melanoma	0.000134	0.062	CrCbGaD
Loperamide—Tamoxifen—ABCB1—melanoma	9.26e-05	0.0429	CrCbGaD
Loperamide—Methadone—ABCB1—melanoma	9.18e-05	0.0425	CrCbGaD
Loperamide—CALM3—Metabolism—PIK3CB—melanoma	4.9e-06	1.37e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—STAT3—melanoma	4.89e-06	1.37e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—IGF1—melanoma	4.89e-06	1.37e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—PTEN—melanoma	4.89e-06	1.37e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—PTEN—melanoma	4.89e-06	1.37e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—PIK3CD—melanoma	4.89e-06	1.37e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—MAPK3—melanoma	4.88e-06	1.37e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—NRAS—melanoma	4.88e-06	1.37e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—MAPK1—melanoma	4.87e-06	1.36e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—EGFR—melanoma	4.87e-06	1.36e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—BRAF—melanoma	4.86e-06	1.36e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—BRAF—melanoma	4.86e-06	1.36e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—PTGS2—melanoma	4.85e-06	1.36e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PIK3CG—melanoma	4.84e-06	1.36e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—ALB—melanoma	4.82e-06	1.35e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—IL6—melanoma	4.82e-06	1.35e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—PIK3CA—melanoma	4.77e-06	1.34e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—MYC—melanoma	4.75e-06	1.33e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—PIK3CB—melanoma	4.74e-06	1.33e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—PIK3CB—melanoma	4.74e-06	1.33e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—STAT3—melanoma	4.73e-06	1.33e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—STAT3—melanoma	4.73e-06	1.33e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—IGF1—melanoma	4.73e-06	1.33e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—IGF1—melanoma	4.73e-06	1.33e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—MAP2K1—melanoma	4.73e-06	1.33e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—NRAS—melanoma	4.72e-06	1.32e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—NRAS—melanoma	4.72e-06	1.32e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—MAPK1—melanoma	4.71e-06	1.32e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—MAPK1—melanoma	4.71e-06	1.32e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—EGFR—melanoma	4.71e-06	1.32e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—EGFR—melanoma	4.71e-06	1.32e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—PIK3CD—melanoma	4.7e-06	1.32e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—PTGS2—melanoma	4.69e-06	1.32e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—PTGS2—melanoma	4.69e-06	1.32e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—MAPK3—melanoma	4.67e-06	1.31e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PPARG—melanoma	4.67e-06	1.31e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—MAPK1—melanoma	4.65e-06	1.3e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—EGFR—melanoma	4.64e-06	1.3e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—TP53—melanoma	4.61e-06	1.29e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—KRAS—melanoma	4.6e-06	1.29e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—MAP2K1—melanoma	4.57e-06	1.28e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—MAP2K1—melanoma	4.57e-06	1.28e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PIK3CG—melanoma	4.56e-06	1.28e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—PIK3CD—melanoma	4.54e-06	1.27e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—PIK3CD—melanoma	4.54e-06	1.27e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—MAPK3—melanoma	4.52e-06	1.27e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—MAPK3—melanoma	4.52e-06	1.27e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—STAT3—melanoma	4.52e-06	1.27e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—NRAS—melanoma	4.51e-06	1.26e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—FGF2—melanoma	4.5e-06	1.26e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—MAPK1—melanoma	4.45e-06	1.25e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—KRAS—melanoma	4.45e-06	1.25e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—KRAS—melanoma	4.45e-06	1.25e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—EGFR—melanoma	4.45e-06	1.25e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—AKT1—melanoma	4.44e-06	1.25e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—HRAS—melanoma	4.41e-06	1.24e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PPARG—melanoma	4.4e-06	1.23e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—KRAS—melanoma	4.39e-06	1.23e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—STAT3—melanoma	4.37e-06	1.23e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—STAT3—melanoma	4.37e-06	1.23e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—NRAS—melanoma	4.36e-06	1.22e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—NRAS—melanoma	4.36e-06	1.22e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—FGF2—melanoma	4.35e-06	1.22e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—FGF2—melanoma	4.35e-06	1.22e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—PTEN—melanoma	4.35e-06	1.22e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—MAPK3—melanoma	4.32e-06	1.21e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—MAPK1—melanoma	4.3e-06	1.21e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—MAPK1—melanoma	4.3e-06	1.21e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—EGFR—melanoma	4.3e-06	1.21e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—EGFR—melanoma	4.3e-06	1.21e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—PIK3CB—melanoma	4.26e-06	1.19e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PIK3CD—melanoma	4.26e-06	1.19e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—PTEN—melanoma	4.23e-06	1.19e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—PIK3CA—melanoma	4.22e-06	1.18e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—IL6—melanoma	4.22e-06	1.18e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—PTGS2—melanoma	4.22e-06	1.18e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—MDM2—melanoma	4.21e-06	1.18e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—ALB—melanoma	4.2e-06	1.18e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—KRAS—melanoma	4.2e-06	1.18e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—MYC—melanoma	4.2e-06	1.18e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—MAPK3—melanoma	4.18e-06	1.17e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—MAPK3—melanoma	4.18e-06	1.17e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—ERBB2—melanoma	4.15e-06	1.16e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—ABCB1—melanoma	4.14e-06	1.16e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—MAPK1—melanoma	4.11e-06	1.15e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—EGFR—melanoma	4.11e-06	1.15e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—PIK3CB—melanoma	4.09e-06	1.15e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—PTEN—melanoma	4.09e-06	1.15e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—PTEN—melanoma	4.09e-06	1.15e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—PIK3CA—melanoma	4.09e-06	1.15e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—PIK3CA—melanoma	4.09e-06	1.15e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—MDM2—melanoma	4.07e-06	1.14e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—MDM2—melanoma	4.07e-06	1.14e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—KRAS—melanoma	4.06e-06	1.14e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—KRAS—melanoma	4.06e-06	1.14e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—MYC—melanoma	4.06e-06	1.14e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—MYC—melanoma	4.06e-06	1.14e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—PIK3CA—melanoma	4.03e-06	1.13e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—ERBB2—melanoma	4.01e-06	1.12e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—ERBB2—melanoma	4.01e-06	1.12e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PIK3CD—melanoma	4.01e-06	1.12e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—MAPK1—melanoma	3.97e-06	1.11e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—MAPK1—melanoma	3.97e-06	1.11e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—EGFR—melanoma	3.97e-06	1.11e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—EGFR—melanoma	3.97e-06	1.11e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—PIK3CB—melanoma	3.96e-06	1.11e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—PIK3CB—melanoma	3.96e-06	1.11e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—ALB—melanoma	3.96e-06	1.11e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CXCL8—melanoma	3.93e-06	1.1e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—HRAS—melanoma	3.91e-06	1.1e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—TP53—melanoma	3.9e-06	1.09e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—AKT1—melanoma	3.9e-06	1.09e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—KRAS—melanoma	3.88e-06	1.09e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—PIK3CA—melanoma	3.86e-06	1.08e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CDKN1B—melanoma	3.84e-06	1.08e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PRKCA—melanoma	3.81e-06	1.07e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CXCL8—melanoma	3.81e-06	1.07e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CXCL8—melanoma	3.81e-06	1.07e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—HRAS—melanoma	3.78e-06	1.06e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—HRAS—melanoma	3.78e-06	1.06e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—ERCC2—melanoma	3.78e-06	1.06e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CASP3—melanoma	3.77e-06	1.06e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—IL2—melanoma	3.76e-06	1.05e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—KRAS—melanoma	3.75e-06	1.05e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—KRAS—melanoma	3.75e-06	1.05e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—IL6—melanoma	3.74e-06	1.05e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—PIK3CA—melanoma	3.73e-06	1.05e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—PIK3CA—melanoma	3.73e-06	1.05e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—HRAS—melanoma	3.73e-06	1.05e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CDKN1B—melanoma	3.72e-06	1.04e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CDKN1B—melanoma	3.72e-06	1.04e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PIK3CB—melanoma	3.71e-06	1.04e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—PTEN—melanoma	3.68e-06	1.03e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PTGS2—melanoma	3.68e-06	1.03e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CCND1—melanoma	3.66e-06	1.03e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CASP3—melanoma	3.64e-06	1.02e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CASP3—melanoma	3.64e-06	1.02e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—IL2—melanoma	3.64e-06	1.02e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—IL2—melanoma	3.64e-06	1.02e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CTNNB1—melanoma	3.63e-06	1.02e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—IL6—melanoma	3.62e-06	1.01e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—IL6—melanoma	3.62e-06	1.01e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—HRAS—melanoma	3.57e-06	1e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—IL6—melanoma	3.57e-06	1e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—PIK3CA—melanoma	3.56e-06	9.99e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—MMP9—melanoma	3.56e-06	9.98e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CDKN1A—melanoma	3.55e-06	9.94e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CCND1—melanoma	3.55e-06	9.94e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CCND1—melanoma	3.55e-06	9.94e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—PTEN—melanoma	3.54e-06	9.92e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—NFKB1—melanoma	3.52e-06	9.87e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CTNNB1—melanoma	3.51e-06	9.84e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CTNNB1—melanoma	3.51e-06	9.84e-06	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PIK3CB—melanoma	3.5e-06	9.8e-06	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PTGS2—melanoma	3.46e-06	9.71e-06	CbGpPWpGaD
Loperamide—CALM2—Immune System—HRAS—melanoma	3.45e-06	9.68e-06	CbGpPWpGaD
Loperamide—CALM1—Immune System—HRAS—melanoma	3.45e-06	9.68e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—AKT1—melanoma	3.45e-06	9.67e-06	CbGpPWpGaD
Loperamide—CALM1—Disease—PIK3CA—melanoma	3.45e-06	9.66e-06	CbGpPWpGaD
Loperamide—CALM2—Disease—PIK3CA—melanoma	3.45e-06	9.66e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—MMP9—melanoma	3.44e-06	9.65e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—MMP9—melanoma	3.44e-06	9.65e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CDKN1A—melanoma	3.43e-06	9.61e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CDKN1A—melanoma	3.43e-06	9.61e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—PTEN—melanoma	3.42e-06	9.59e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—PTEN—melanoma	3.42e-06	9.59e-06	CbGpPWpGaD
Loperamide—CALM3—Immune System—IL6—melanoma	3.42e-06	9.58e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—NFKB1—melanoma	3.41e-06	9.55e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—NFKB1—melanoma	3.41e-06	9.55e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—AKT1—melanoma	3.34e-06	9.36e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—AKT1—melanoma	3.34e-06	9.36e-06	CbGpPWpGaD
Loperamide—CALM2—Immune System—IL6—melanoma	3.31e-06	9.27e-06	CbGpPWpGaD
Loperamide—CALM1—Immune System—IL6—melanoma	3.31e-06	9.27e-06	CbGpPWpGaD
Loperamide—CALM3—Disease—HRAS—melanoma	3.3e-06	9.24e-06	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—AKT1—melanoma	3.29e-06	9.23e-06	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PTEN—melanoma	3.21e-06	8.99e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—VEGFA—melanoma	3.19e-06	8.96e-06	CbGpPWpGaD
Loperamide—CALM2—Disease—HRAS—melanoma	3.19e-06	8.94e-06	CbGpPWpGaD
Loperamide—CALM1—Disease—HRAS—melanoma	3.19e-06	8.94e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—STAT3—melanoma	3.16e-06	8.87e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—NRAS—melanoma	3.16e-06	8.85e-06	CbGpPWpGaD
Loperamide—CALM3—Disease—IL6—melanoma	3.16e-06	8.85e-06	CbGpPWpGaD
Loperamide—CALM3—Immune System—AKT1—melanoma	3.15e-06	8.84e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—VEGFA—melanoma	3.09e-06	8.66e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—VEGFA—melanoma	3.09e-06	8.66e-06	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—PIK3CA—melanoma	3.07e-06	8.6e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—STAT3—melanoma	3.06e-06	8.58e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—STAT3—melanoma	3.06e-06	8.58e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—NRAS—melanoma	3.05e-06	8.56e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—NRAS—melanoma	3.05e-06	8.56e-06	CbGpPWpGaD
Loperamide—CALM1—Disease—IL6—melanoma	3.05e-06	8.56e-06	CbGpPWpGaD
Loperamide—CALM2—Disease—IL6—melanoma	3.05e-06	8.56e-06	CbGpPWpGaD
Loperamide—CALM1—Immune System—AKT1—melanoma	3.05e-06	8.55e-06	CbGpPWpGaD
Loperamide—CALM2—Immune System—AKT1—melanoma	3.05e-06	8.55e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—MAPK3—melanoma	3.02e-06	8.47e-06	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PTEN—melanoma	3.02e-06	8.47e-06	CbGpPWpGaD
Loperamide—CALM3—Metabolism—PIK3CA—melanoma	2.98e-06	8.37e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PIK3CG—melanoma	2.98e-06	8.36e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—MYC—melanoma	2.94e-06	8.24e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—MAPK3—melanoma	2.92e-06	8.2e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—MAPK3—melanoma	2.92e-06	8.2e-06	CbGpPWpGaD
Loperamide—CALM3—Disease—AKT1—melanoma	2.91e-06	8.16e-06	CbGpPWpGaD
Loperamide—CALM1—Metabolism—PIK3CA—melanoma	2.89e-06	8.09e-06	CbGpPWpGaD
Loperamide—CALM2—Metabolism—PIK3CA—melanoma	2.89e-06	8.09e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PPARG—melanoma	2.88e-06	8.07e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—MAPK1—melanoma	2.88e-06	8.06e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—EGFR—melanoma	2.88e-06	8.06e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—MYC—melanoma	2.84e-06	7.97e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—MYC—melanoma	2.84e-06	7.97e-06	CbGpPWpGaD
Loperamide—CALM2—Disease—AKT1—melanoma	2.82e-06	7.89e-06	CbGpPWpGaD
Loperamide—CALM1—Disease—AKT1—melanoma	2.82e-06	7.89e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—MAPK1—melanoma	2.78e-06	7.8e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—MAPK1—melanoma	2.78e-06	7.8e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—EGFR—melanoma	2.78e-06	7.8e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—EGFR—melanoma	2.78e-06	7.8e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—KRAS—melanoma	2.72e-06	7.61e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—KRAS—melanoma	2.63e-06	7.37e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—KRAS—melanoma	2.63e-06	7.37e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PIK3CD—melanoma	2.62e-06	7.35e-06	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—PIK3CA—melanoma	2.6e-06	7.28e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—ALB—melanoma	2.59e-06	7.26e-06	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—AKT1—melanoma	2.51e-06	7.02e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—PIK3CA—melanoma	2.5e-06	7e-06	CbGpPWpGaD
Loperamide—CALM3—Metabolism—AKT1—melanoma	2.44e-06	6.84e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—TP53—melanoma	2.41e-06	6.77e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—PIK3CA—melanoma	2.41e-06	6.77e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—PIK3CA—melanoma	2.41e-06	6.77e-06	CbGpPWpGaD
Loperamide—CALM2—Metabolism—AKT1—melanoma	2.36e-06	6.61e-06	CbGpPWpGaD
Loperamide—CALM1—Metabolism—AKT1—melanoma	2.36e-06	6.61e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—TP53—melanoma	2.34e-06	6.55e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—TP53—melanoma	2.34e-06	6.55e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—HRAS—melanoma	2.31e-06	6.47e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PIK3CB—melanoma	2.29e-06	6.41e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PTGS2—melanoma	2.26e-06	6.35e-06	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PIK3CA—melanoma	2.26e-06	6.34e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—HRAS—melanoma	2.23e-06	6.26e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—HRAS—melanoma	2.23e-06	6.26e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—IL6—melanoma	2.21e-06	6.2e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—IL6—melanoma	2.14e-06	5.99e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—IL6—melanoma	2.14e-06	5.99e-06	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PIK3CA—melanoma	2.13e-06	5.98e-06	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—AKT1—melanoma	2.12e-06	5.95e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—AKT1—melanoma	2.04e-06	5.72e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PTEN—melanoma	1.98e-06	5.54e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—AKT1—melanoma	1.97e-06	5.53e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—AKT1—melanoma	1.97e-06	5.53e-06	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—AKT1—melanoma	1.85e-06	5.18e-06	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—AKT1—melanoma	1.74e-06	4.88e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PIK3CA—melanoma	1.39e-06	3.91e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—AKT1—melanoma	1.14e-06	3.19e-06	CbGpPWpGaD
